Pay in 4 interest-free payments of $6.90 Learn more
Ships within 48 hours · Estimated delivery Jul 29 - Aug 3
Preclinical models used oral dosing at 50100mg/kg body weight, but human-equivalent subcutaneous protocols typically range from 30mg to 50mg per injection, administered once daily
Speak to a real person now: Call/Text our clinic at (801) 318-4260 to learn more about our CJC-1295+Ipamorelin Sublingual Oral Dissolving Peptides Strips and how they may support your recovery plan and goals
DSIP is a naturally occurring peptide linked to sleep regulation and stress response
Disclosure of interest: The authors of this study have nothing to disclose Poster Session I - RISK FACTORS - PRIMARY AND SECONDAR PREVENTION 05.00 - RISK FACTORS AND PREVENTION (PRIMARY AND SECONDARY) - 05.04 - STROKE COMPLICATIONS P403 - ESOC25-2347 POST-STROKE EPILEPSY IN THE ERA OF ADVANCED REPERFUSION THERAPIES Catarina Guedes Vaz 1 , Alexandre Dias 2,3 , Ricardo Varela 1 , Isabel Silva 3 , Ana Moutinho 2,3 , Pedro Castro 4 , Bruno Castro 4 , Carla Oliveira 2,5 , Henrik Zetterberg 6 , Johan Gobom 6 , Manuel Correia 1,3 , Rui Magalhes 3 , Lus Maia 1,2,3 1 Servio de Neurologia, Centro Hospitalar Universitrio de Santo Antnio, ULSdSA, Porto, Portugal, 2 Instituto de Investigao e Inovao em Sade (i3S), Universidade do Porto, Porto, Portugal, 3 Instituto de Cincias Biomdicas Abel Salazar (ICBAS), Universidade do Porto, Porto, Portugal, 4 Servio de Neurologia, Centro Hospitalar Universitrio de So Joo, ULSdSJ, Porto, Portugal, 5 Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), Porto, Portugal, 6 Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, University of Gothenburg (UGOT), Gothenburg, Sweden Background and Aims: Post-stroke epilepsy (PSE) is a significant comorbidity in stroke survivors
US$ 20.28
US$ 28.78
US$ 26.02
US$ 28.00
US$ 23.33
US$ 26.30
US$ 27.20